Pratibha Garg

Pratibha Garg

Auto-generated profile, based on publicly available information

Pratibha Garg

Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh, India

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2024 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NVNipun Verma
Nipun Verma
ARAkash Roy
Akash Roy
AVARUN VALSAN
ARUN VALSAN
PGPratibha Garg
Pratibha Garg
SRSamonee Ralmilay
Samonee Ralmilay
ADAjay Duseja
Ajay Duseja
INTRODUCTION: Hospitalized patients with acute decompensation (AD) of cirrhosis are at risk of progressing to acute-on-chronic liver failure (ACLF), significantly increasing their mortality. The aim of this study was to identify key predictors and patient trajectories predisposing to ACLF. METHODS: In this multicenter, prospective study spanning 2 years, clinical, biochemical, and 90-day survival data were collected from 625 patients with AD (European Association for the Study of the Liver criteria) across North, South, and East India. We divided the cohort into a Derivation cohort (DC: 318 patients) and a Validation cohort (VC: 307 patients). Predictive models for pre-ACLF were derived, validated, and compared with established scores such as model for end-stage liver disease (MELD) 3.0 and chronic liver failure Consortium acute decompensation. RESULTS: Of 625 patients (mean age 49 years, 83% male, 77.5% with alcohol-related liver disease), 32.2% progressed to ACLF. Patients progressing to ACLF showed significantly higher bilirubin (10.9 vs 8.1 mg/dL), leukocyte counts (9,400 vs 8,000 per mm3), international normalized ratio (1.9 vs 1.8), and MELD 3.0 (28 vs 25) but lower sodium (131 vs 134 mEq/L) and survival (62% vs 86%) compared with those without progression (P < 0.05) in the DC. Consistent results were noted with alcohol-associated hepatitis, infection and hepatic encephalopathy as additional risk factors in VC. Liver failure at presentation (odds ratio: 2.4 [in DC], 6.9 [in VC]) and the 7-day trajectories of bilirubin, international normalized ratio, and MELD 3.0 significantly predicted ACLF progression (P < 0.001). A new pre-ACLF model showed superior predictive capability (area under the curve of 0.71 in DC and 0.82 in VC) compared with MELD 3.0 and chronic liver failure Consortium acute decompensation scores (P < 0.05). DISCUSSION: Approximately one-third of AD patients in this Indian cohort rapidly progressed to ACLF, resulting in high mortality. Early identification of patients at risk can guide targeted interventions to prevent ACLF.

21 November 2025 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
NVNipun Verma
Nipun Verma
AVARUN VALSAN
ARUN VALSAN
PGPratibha Garg
Pratibha Garg
SSShreeja Sarabu
Shreeja Sarabu
PKParminder Kaur
Parminder Kaur
ADAjay Duseja
Ajay Duseja
INTRODUCTION: Invasive fungal infections (IFIs) in acute-on-chronic liver failure (ACLF) are associated with transplant delistings, high morbidity, and mortality. An optimal strategy of antifungal therapy in this setting remains uncertain. We compared suspicion-based (empirical) with investigation-driven (diagnostic/biomarker-driven-pre-emptive) antifungal therapy among patients with ACLF in a high-burden setting. METHODS: In this parallel-group, pragmatic, randomized trial with blinded endpoint adjudication (NCT04157465), 216 hospitalized ACLF patients with predefined host and clinical factors for IFI were randomized (1:1) to empirical antifungal therapy at enrolment or diagnostic/biomarker-driven-pre-emptive therapy on laboratory, radiological, or mycological confirmation. Biomarker-guided and culture-guided antifungal stewardship protocols were implemented in both groups. The primary outcome was 28-day overall survival. Secondary outcomes included in-hospital mortality, changes in severity scores, adverse events, and cost-effectiveness. Heterogeneous treatment effects were explored through causal tree analysis. RESULTS: Empirical antifungal therapy significantly improved 28-day survival compared with diagnostic/biomarker-driven-pre-emptive therapy (35% vs 13%; hazard ratio: 0.64, 95% confidence interval: 0.47–0.88; P = 0.005). Treatment success (37.4% vs 16.9%; P = 0.002) and IFI resolution (45.8% vs 22.5%, P = 0.001) were higher; in-hospital and IFI-attributable mortality (55.6% vs 75.9%; P = 0.003) was lower in the empirical group. Fewer adverse events with greater quality-of-life years gains (29.9 vs 10.1) and an incremental cost-effectiveness ratio of international normalized ratio 1,42,737 were observed with empirical therapy. The survival benefit was maximum among patients aged 40 years or older with cardiovascular failure but without respiratory failure. DISCUSSION: Early empirical antifungal therapy within a structured stewardship framework improves survival in patients with ACLF and IFIs. Timely recognition, rapid diagnostics, and individualized antifungal strategies are essential to bridge these high-risk patients toward recovery or definitive therapies.

24 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
NVNipun Verma
Nipun Verma
PGPratibha Garg
Pratibha Garg
GNGowri Priya Nair
Gowri Priya Nair
AVArathi Venu
Arathi Venu
NJNikhil Sai Jarpula
Nikhil Sai Jarpula
RJRajiv Jalan
Rajiv Jalan
Background & Aims: ACLF is defined differently by APASL (acute hepatic dysfunction) and by organ failure-based frameworks including EASL-CLIF and the recently developed A-TANGO score. Whether these definitions identify competing populations or sequential stages of the same syndrome remains unresolved, with direct implications for the timing of intervention. We tested whether APASL-defined ACLF can be integrated into the A-TANGO framework to identify a clinically actionable patient population. Methods: 4,024 patients hospitalised with acute decompensation of cirrhosis in a multicentre cohort were classified simultaneously by APASL and A-TANGO criteria. Mortality, progression to A-TANGO ACLF among A-TANGO-negative patients, and reversal of ACLF were assessed using Fine-Gray competing-risk models with death as a competing event. EASL-CLIF analyses were performed as sensitivity analyses. Results: A-TANGO-negative/APASL-positive patients comprised 8.7% of the cohort and had higher 90-day mortality than A-TANGO-negative/APASL-negative patients (22.3% vs 14.4%, p=0.001), despite similar 28-day mortality. Once A-TANGO ACLF was established, 28-day mortality was high irrespective of APASL status (45.4% in APASL-positive and 56.0% in APASL-negative patients). Among A-TANGO-negative patients, 53.5% of APASL-positive vs 27.9% of APASL-negative patients progressed to A-TANGO ACLF within 28 days, with APASL positivity independently predicting progression (adjusted sHR: 2.30, 95%CI: 1.90-2.77). Within A-TANGO-negative/APASL-negative patients an A-TANGO OF score ≥8 independently enriched for progression (52% vs 19%). A-TANGO reversal occurred in 17.1% and was independently reduced by APASL positivity (adjusted sHR: 0.756, 95%CI: 0.586-0.975), while APASL reversal was rare (4.0%). EASL-CLIF sensitivity analyses were directionally consistent. Conclusions: APASL-defined ACLF does not compete with A-TANGO; it occupies an upstream position on the same disease trajectory. A-TANGO-negative/APASL-positive patients and A-TANGO-negative/APASL-negative patients with A-TANGO OF ≥8 represent complementary pre-ACLF populations suitable for prevention trials and enrichment strategies. Abstract Figure: